VC-backed Vyome appoints two to board

By Iris Dorbian — 4 months ago

New Delhi, India-based Vyome Biosciences, a clinical stage dermatology based biopharmaceutical company, has named Dr. Bhaskar Chaudhuri and Alan Rosling to its board of directors. Chaudhuri is an operating partner at Frazier Healthcare Ventures while Rosling is a is senior advisor at Navam Capital. Vyome’s backers included Kalaari Capital, Sabre Partners, Aarin Capital and Navam Capital.

Continue

VC-backed ProNAi files for IPO

By Iris Dorbian — 8 months ago

Vancouver-based ProNAi Therapeutics, a developer of nucleic acid therapeutics, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The stock will list on the NASDAQ under the ticker symbol “DNAI.” Jefferies LLC and BofA Merrill Lynch will serve as the lead underwriters. ProNAi’s backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue

VC-backed Glaukos Corp files for IPO

By Iris Dorbian — 9 months ago

Laguna Hills, California-based Glaukos Corporation, a developer of treatments for glaucoma, has filed for an IPO. The number of shares that will be sold as well as the IPO’s pricing terms have yet to be set. The company plans on trading the stock on the NYSE under the ticker symbol “GKOS.” J.P. Morgan, BofA Merrill Lynch and Goldman, Sachs & Co are serving as the lead underwriters. Glaukos’ backers include OrbiMed Advisors, Frazier Healthcare Ventures, InterWest Partners, Domain Associates, Fjord Ventures, Montreaux Equity Partners and Versant Ventures

Continue

VC-backed ProNai adds five to senior management staff

By Iris Dorbian — 1 year ago

ProNAi Therapeutics, a developer of nucleic acid therapeutics, has expanded its senior management team with five additions. Joining the firm are Dr. Angie You as chief business and strategy officer and head of commercial; Wendy Chapman as senior vice president of clinical operations; Chandra Lovejoy as senior vice president of global regulatory affairs and quality; Emma McCann as vice president of program management; and James Smith as vice president of corporate affairs. ProNAi’s backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue

ProNAi Therapeutics raises Series D

By Angela Sormani — 2 years ago

ProNAi Therapeutics, a developer of novel nucleic acid therapeutics has closed an oversubscribed $59.5 million Series D financing. The round was led by Vivo Capital and included other new investors Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.

Continue

Tobira Therapeutics Appoints Three Execs

By Angela Sormani — 3 years ago

Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from […]

Continue

Collegium Pharmaceutical Raises $22.5M

By Staff Report — 4 years ago

Collegium Pharmaceutical Inc., a specialty pharmaceutical company focused on treatments for chronic pain, has raised $22.5 million in Series B financing. Longitude Capital and Skyline Ventures led the round. Series A investors Frazier Healthcare Ventures and Boston Millennia Partners also participated in the round. PRESS RELEASE Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on […]

Continue

PowerVision Completes Funding Round

By Angela Sormani — 4 years ago

PowerVision, a private company developing an accommodating intraocular lens, had added Johnson & Johnson Development Corporation to its list of investors in a recent closing of its Series C financing. Current investors, Venrock, Advanced Technology Ventures, and Frazier Healthcare Ventures, also participated in the round. The closing brings PowerVision’s Series C financing round to a […]

Continue

peHUB First Read

By Jonathan Marino — 4 years ago

Burger King: Cashing in on lazy fat-arses

No Experience Necessary! HuffPo’s latest hire

Ouch: Backer calls Kickstarter “worst project ever

Stop Snitchin’! FBI bags more in insider trading probes

Down in the Dumps: Indian VC Funding Falls by Half

PE Magnetism: Hong Kong draws in the money

Take a Pill: Capsule is a one stop shop for private events

New Year Blues: Sony Ericsson posts a loss in Q4 2011

Is the Biotech Venture Model broken? Frazier Healthcare Ventures is trying to fix it

Money is Money: Anyone can invest, the challenge is priming portfolio companies for big growth

Bust! Eastman Kodak files for Chapter 11

Japan Loses Appeal: Certain PE firms scale back Japanese operations

Hot Property: Blackstone pursuing further opportunities in China after profitable exit on Evergrande

Continue

Tobira Therapeutics Names Andrew Hindman As President and Chief Executive

By Eamon — 5 years ago

Tobira Therapeutics Inc. hired Andrew Hindman as president and chief executive officer. Hindman was Nodality Inc.’s senior vice president of corporate development.Tobira is a N.J.-based biopharmaceutical company that is focused on developing therapies for HIV infection. It is backed by Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

Continue

From the Filings…

5 years ago

(Recent funding news based on Form D filings with the S.E.C.) E-commerce platform provider Rearden Commerce has raised $46.98 million in a new round of financing, according to a filing with the S.E.C. Rearden previously raised roughly $200 million from venture investors including Foundation Capital, Oak Investment Partners, Empire Capital Partners, American Express and Chase […]

Continue

Confirmed: Chimerix’s $45 Million Fundraising

By PEHub Administrator — 5 years ago

As peHUB.com reported late last week, Chimerix Inc., the pharmaceutical drug company working on orally-available antiviral therapeutics has completed a $45 million fundraising. New investors include Pappas Ventures and Morningside Group; other investors include Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Continue

Incline Therapeutics Raises $43 Million, Signs Acquisition Option

By PEHub Administrator — 6 years ago

Incline Therapeutics Inc., a hospital-focused specialty pharma startup, has raised $43 million in Series A funding. Frazier Healthcare Ventures led the round, and was joined by 5AM Ventures, Technology Partners, Adams Street Partners, Saints Capital Partners and Emergent Medical Partners. Also receiving shares was Cadence Pharmaceuticals Inc. (Nasdaq: CADX), which signed an option to acquire Incline for up to $285 million.

In related news, Incline agreed to acquire the global rights to IONSYS, patient-controlled analgesia for adult inpatients requiring opioids following surgery, from ALZA Corp.

Continue

Achaogen Raises $65 Million

By PEHub Administrator — 6 years ago

Achaogen, a San Francisco-based developer of antibiotics to treat life-threatening, multi-drug resistant bacterial infections, has raised $65 million in Series C funding. Frazier Healthcare Ventures led the round, and was joined by Alta Partners and return backers 5AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust. The company previously raised around $42 million.

Continue

Clovis Oncology Raises $145 Million

By PEHub Administrator — 7 years ago

Clovis Oncology, a developer of anti-cancer agents based in Boulder, Colo., secured $145 million in financing from Domain Associates, New Enterprise Associates (NEA), Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, ProQuest Investments and the Company’s management team. Press release: Clovis Oncology, Inc., a company focused on acquiring, developing and commercializing innovative anti-cancer agents in […]

Continue